Related Experiment Video
Updated: Jul 18, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
An Integrated Arterial Remodeling Hydrogel for Preventing Restenosis After Angioplasty
Chenxing Fu1,2, Qiu Li1, Minghui Li2
1Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital, School of Biomedical Engineering, Guangzhou Medical University, Guangzhou, 510260, China.
Insights
A novel stent-free hydrogel coating, Cur-NO-Gel, effectively prevents restenosis after angioplasty. It releases nitric oxide and curcumin, promoting healing and reducing vascular stenosis for improved patient outcomes.
Area of Science:
- Biomaterials Science
- Cardiovascular Research
- Drug Delivery Systems
Background:
- Restenosis post-angioplasty is a major cause of coronary heart disease recurrence.
- Current drug-eluting stents have limitations in function and long-term safety.
- There is a need for advanced anti-stenosis therapies.
Purpose of the Study:
- To develop a stent-free anti-stenosis drug coating using a peptide hydrogel.
- To create a dual-release system for nitric oxide (NO) and curcumin (Cur).
- To evaluate the efficacy of the hydrogel in preventing vascular stenosis.
Main Methods:
- Formation of a peptide hydrogel encapsulating curcumin and a NO-donor peptide conjugate.
- In vitro assessment of endothelial cell protection, smooth muscle cell activation, and fibroblast suppression.
- In vivo evaluation in an angioplasty model for effects on reendothelialization, neointima hyperplasia, and remodeling.
Main Results:
- Cur-NO-Gel demonstrated protection against oxidative stress and inhibited vascular cell activation.
- The hydrogel effectively inhibited neointima hyperplasia and constrictive remodeling in vivo.
- Cur-NO-Gel promoted reendothelialization, indicating improved vascular healing.
Conclusions:
- The Cur-NO-Gel hydrogel offers a promising stent-free approach to combat restenosis.
- This dual-drug delivery system shows potential for a new generation of clinical angioplasty treatments.
- The study provides proof of concept for advanced anti-stenosis therapies.
Abstract:
The high incidence of restenosis after angioplasty has been the leading reason for the recurrence of coronary heart disease, substantially increasing the mortality risk for patients. However, current anti-stenosis drug-eluting stents face challenges due to their limited functions and long-term safety concerns, significantly compromising their therapeutic effect. Herein, a stent-free anti-stenosis drug coating (denoted as Cur-NO-Gel) based on a peptide hydrogel is proposed. This hydrogel is formed by assembling a nitric oxide (NO) donor-peptide conjugate as a hydrogelator and encapsulating curcumin (Cur) during the assembly process. Cur-NO-Gel has the capability to release NO upon β-galactosidase stimulation and gradually release Cur through hydrogel hydrolysis. The in vitro experiments confirmed that Cur-NO-Gel protects vascular endothelial cells against oxidative stress injury, inhibits cellular activation of vascular smooth muscle cells, and suppresses adventitial fibroblasts. Moreover, periadventitial administration of Cur-NO-Gel in the angioplasty model demonstrate its ability to inhibit vascular stenosis by promoting reendothelialization, suppressing neointima hyperplasia, and preventing constrictive remodeling. Therefore, the study provides proof of concept for designing a new generation of clinical drugs in angioplasty.
